论文部分内容阅读
由血小板释放的血栓素A_2(TXA_2)具有极强的促血小板聚集和缩血管作用、由血管壁产生的前列环素(PGI_2)具有极强的抑制血小板聚集和扩血管作用。因此,目前认为,TXA_2/PGI_2是存在于体内的一对极为精巧的分子调节机制。近年来的一些研究表明,TXA_2/PGI_2的比例失衡,在糖尿病大血管和微血管病变的发生发展中有重要作用。本文探讨了同是微血管病变为主要发病基础的糖尿病肾病和视网膜病变患者,血浆TXA_2和PGI_2的变化特点,并就其临床意义作一初步控讨。
Thromboxane A 2 (TXA 2) released from platelets has strong platelet aggregation and vasoconstriction. PGI 2 produced by the vascular wall is highly effective in inhibiting platelet aggregation and vasodilation. Therefore, it is currently believed that TXA_2 / PGI_2 is a pair of extremely sophisticated molecular regulatory mechanisms present in the body. In recent years, some studies have shown that the proportion of TXA 2 / PGI 2 imbalance in the occurrence and development of diabetic macrovascular and microvascular plays an important role. This article discusses the same microvascular disease as the main pathogenesis of diabetic nephropathy and retinopathy, plasma TXA 2 and PGI 2 changes, and its clinical significance of a preliminary review.